Thioridazine: A Non-Antibiotic Drug Highly Effective, in Combination with First Line Anti-Tuberculosis Drugs, against Any Form of Antibiotic Resistance of Mycobacterium tuberculosis Due to Its Multi-Mechanisms of Action.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 28098814)

Published in Antibiotics (Basel) on January 14, 2017

Authors

Leonard Amaral1,2, Miguel Viveiros3

Author Affiliations

1: Insititute of Hygiene and Tropical Medicine, Universidade Nova de Lisboa, Lisbon 1349-008, Portugal. lamaral@ihmt.unl.pt.
2: Institute of Medical Microbiology and Immunobiology, University of Szeged, Szeged 6720, Hungary. lamaral@ihmt.unl.pt.
3: Unidade de Microbiologia Médica, Global Health and Tropical Medicine, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisbon 1349-008, Portugal. MViveiros@ihmt.unl.pt.

Articles cited by this

(truncated to the top 100)

Killing activity of neutrophils is mediated through activation of proteases by K+ flux. Nature (2002) 7.53

M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell (2007) 4.90

Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell (2011) 3.42

QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics (2013) 2.80

Extensively drug-resistant tuberculosis in the United States, 1993-2007. JAMA (2008) 2.63

Retracted The large-conductance Ca2+-activated K+ channel is essential for innate immunity. Nature (2004) 1.85

Characteristics and costs of multidrug-resistant tuberculosis in-patient care in the United States, 2005-2007. Int J Tuberc Lung Dis (2016) 1.72

Antibiotic stress, genetic response and altered permeability of E. coli. PLoS One (2007) 1.50

Diversity in Mycobacterium tuberculosis mannosylated cell wall determinants impacts adaptation to the host. Tuberculosis (Edinb) (2010) 1.50

The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance. Antimicrob Agents Chemother (2012) 1.48

Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis. PLoS One (2012) 1.46

Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy. Tuberculosis (Edinb) (2014) 1.43

Persistence of a highly resistant strain of tuberculosis in New York City during 1990-1999. J Infect Dis (2003) 1.41

Steady-state kinetics and inhibitory action of antitubercular phenothiazines on mycobacterium tuberculosis type-II NADH-menaquinone oxidoreductase (NDH-2). J Biol Chem (2006) 1.35

A Mycobacterium tuberculosis sigma factor network responds to cell-envelope damage by the promising anti-mycobacterial thioridazine. PLoS One (2010) 1.32

Inducement and reversal of tetracycline resistance in Escherichia coli K-12 and expression of proton gradient-dependent multidrug efflux pump genes. Antimicrob Agents Chemother (2005) 1.31

Isoniazid-induced transient high-level resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2002) 1.30

Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother (2003) 1.30

Nitrate enhances the survival of Mycobacterium tuberculosis during inhibition of respiration. J Bacteriol (2008) 1.26

Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines. Int J Antimicrob Agents (2001) 1.26

Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor. Am J Respir Crit Care Med (2013) 1.23

Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex. Infect Genet Evol (2011) 1.22

Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps. J Antimicrob Chemother (2007) 1.19

Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine. J Antimicrob Chemother (2011) 1.13

Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy. J Antimicrob Chemother (2001) 1.09

Phenothiazine: the seven lives of pharmacology's first lead structure. Drug Discov Today (2011) 1.06

Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: potential use for initial therapy of freshly diagnosed tuberculosis. J Antimicrob Chemother (1996) 1.06

Type II NADH: menaquinone oxidoreductase of Mycobacterium tuberculosis. Infect Disord Drug Targets (2007) 1.06

The role of lysosomes in the cellular distribution of thioridazine and potential drug interactions. Toxicol Appl Pharmacol (1999) 1.02

Voltage gated calcium channels negatively regulate protective immunity to Mycobacterium tuberculosis. PLoS One (2009) 1.02

Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners. Antimicrob Agents Chemother (2013) 1.02

Extensively drug-resistant tuberculosis: epidemiology and management. Clin Epidemiol (2014) 1.02

How Mycobacterium tuberculosis subverts host immune responses. Bioessays (2008) 1.02

Energy metabolism and drug efflux in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2014) 0.99

Transcriptional Adaptation of Drug-tolerant Mycobacterium tuberculosis During Treatment of Human Tuberculosis. J Infect Dis (2015) 0.99

The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis. PLoS One (2010) 0.99

The curative activity of thioridazine on mice infected with Mycobacterium tuberculosis. In Vivo (2007) 0.98

Chlorpromazine: a drug potentially useful for treating mycobacterial infections. Chemotherapy (1992) 0.98

Autophagosome maturation and lysosomal fusion. Essays Biochem (2013) 0.96

Totally drug-resistant tuberculosis and adjunct therapies. J Intern Med (2014) 0.92

Voltage coupling of primary H+ V-ATPases to secondary Na+- or K+-dependent transporters. J Exp Biol (2009) 0.92

Inhibitors of mycobacterial efflux pumps as potential boosters for anti-tubercular drugs. Expert Rev Anti Infect Ther (2012) 0.91

Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. J Thorac Dis (2015) 0.91

Contribution of lysosomal trapping to the total tissue uptake of psychotropic drugs. Pharmacol Toxicol (1997) 0.91

Phenothiazines, bacterial efflux pumps and targeting the macrophage for enhanced killing of intracellular XDRTB. In Vivo (2010) 0.91

The added effect of thioridazine in the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis (2012) 0.88

Studies on antituberculotic action of some phenothiazine derivatives in vitro. Zentralbl Bakteriol Orig A (1977) 0.88

New patentable use of an old neuroleptic compound thioridazine to combat tuberculosis: a gene regulation perspective. Recent Pat Antiinfect Drug Discov (2011) 0.88

The antibacterial effect of selected phenothiazines and thioxanthenes on slow-growing mycobacteria. Acta Pathol Microbiol Immunol Scand B (1986) 0.87

Novel drugs against tuberculosis: a clinician's perspective. Eur Respir J (2014) 0.87

Immunological protection against mycobacterium tuberculosis infection. Crit Rev Immunol (2006) 0.87

Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment. Eur Respir J (2015) 0.87

Reduced emergence of isoniazid resistance with concurrent use of thioridazine against acute murine tuberculosis. Antimicrob Agents Chemother (2014) 0.87

Efflux pumps of Gram-negative bacteria: what they do, how they do it, with what and how to deal with them. Front Pharmacol (2014) 0.86

Synergic effect of chlorpromazine on the activity of some antibiotics. J Antimicrob Chemother (1992) 0.84

In vitro and ex vivo activity of thioridazine derivatives against Mycobacterium tuberculosis. Int J Antimicrob Agents (2007) 0.84

Thioridazine induces apoptosis of multidrug-resistant mouse lymphoma cells transfected with the human ABCB1 and inhibits the expression of P-glycoprotein. Anticancer Res (2011) 0.83

Ethidium bromide efflux by Salmonella: modulation by metabolic energy, pH, ions and phenothiazines. Int J Antimicrob Agents (2011) 0.83

pH Modulation of efflux pump activity of multi-drug resistant Escherichia coli: protection during its passage and eventual colonization of the colon. PLoS One (2009) 0.83

Latent tuberculosis: is there a role for thioridazine? Recent Pat Antiinfect Drug Discov (2011) 0.83

Thioridazine: the good and the bad. Recent Pat Antiinfect Drug Discov (2011) 0.83

Safety and efficacy of thioridazine as salvage therapy in Indian patients with XDR-TB. Recent Pat Antiinfect Drug Discov (2011) 0.83

Inhibitors of Ca2+ and K+ transport enhance intracellular killing of M. tuberculosis by non-killing macrophages. In Vivo (2008) 0.82

Targeting the human macrophage with combinations of drugs and inhibitors of Ca2+ and K+ transport to enhance the killing of intracellular multi-drug resistant Mycobacterium tuberculosis (MDR-TB)--a novel, patentable approach to limit the emergence of XDR-TB. Recent Pat Antiinfect Drug Discov (2011) 0.81

Maintenance antipsychotic therapy: is the cure worse than the disease? Am J Psychiatry (1976) 0.81

Effects of chlorpromazine on the cell envelope proteins of Escherichia coli. Antimicrob Agents Chemother (1991) 0.81

"Non-Antibiotics": alternative therapy for the management of MDRTB and MRSA in economically disadvantaged countries. Curr Drug Targets (2006) 0.81

Tuberculosis 2015: Burden, Challenges and Strategy for Control and Elimination. Infect Dis Rep (2016) 0.81

An AcrAB-mediated multidrug-resistant phenotype is maintained following restoration of wild-type activities by efflux pump genes and their regulators. Int J Antimicrob Agents (2009) 0.81

Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis. Ann Clin Microbiol Antimicrob (2016) 0.81

Factors affecting drug concentrations and QT interval during thioridazine therapy. Clin Pharmacol Ther (2007) 0.80

Enhancement of antibiotic activity by efflux inhibitors against multidrug resistant Mycobacterium tuberculosis clinical isolates from Brazil. Front Microbiol (2015) 0.80

Effect of thioridazine stereoisomers on the drug accumulation of mouse lymphoma and human prostate cancer cell lines in vitro. In Vivo (2013) 0.80

Tuberculosis treatment and drug regimens. Cold Spring Harb Perspect Med (2015) 0.79

Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index. Expert Rev Anti Infect Ther (2016) 0.79

Synthetic investigational new drugs for the treatment of tuberculosis. Expert Opin Investig Drugs (2015) 0.78

Role of calcium in the efflux system of Escherichia coli. Int J Antimicrob Agents (2011) 0.78

Sterilizing activity of thioridazine in combination with the first-line regimen against acute murine tuberculosis. Antimicrob Agents Chemother (2014) 0.78

Ion Channel Blockers as Antimicrobial Agents, Efflux Inhibitors, and Enhancers of Macrophage Killing Activity against Drug Resistant Mycobacterium tuberculosis. PLoS One (2016) 0.78

Mechanisms of resistance in bacteria: an evolutionary approach. Open Microbiol J (2013) 0.77

The broad-spectrum antimycobacterial activities of phenothiazines, InVitro: somewhere in all of this there may be patentable potentials. Recent Pat Antiinfect Drug Discov (2011) 0.77

Genetic response of Salmonella enterica serotype Enteritidis to thioridazine rendering the organism resistant to the agent. Int J Antimicrob Agents (2011) 0.77

Thioridazine: an old neuroleptic effective against totally drug resistant tuberculosis. Acta Med Port (2012) 0.77

Prolonged exposure of methicillin-resistant Staphylococcus aureus (MRSA) COL strain to increasing concentrations of oxacillin results in a multidrug-resistant phenotype. Int J Antimicrob Agents (2007) 0.77

Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy. J Med Chem (2015) 0.77

Thioridazine in PLGA nanoparticles reduces toxicity and improves rifampicin therapy against mycobacterial infection in zebrafish. Nanotoxicology (2015) 0.77

Dynamic imaging of the recycling endosomal network in macrophages. Methods Cell Biol (2015) 0.76

Multidrug resistance reversing activity of newly developed phenothiazines on P-glycoprotein (ABCB1)-related resistance of mouse T-lymphoma cells. Anticancer Res (2014) 0.76

Why and how thioridazine in combination with antibiotics to which the infective strain is resistant will cure totally drug-resistant tuberculosis. Expert Rev Anti Infect Ther (2012) 0.76

Phenothiazines as anti-tubercular agents: mechanistic insights and clinical implications. Expert Opin Investig Drugs (2011) 0.76

A Novel Advanced Laboratory Diagnosis to Guide Tuberculosis Drug Therapy. Recent Pat Antiinfect Drug Discov (2015) 0.76

Mechanisms by which thioridazine in combination with antibiotics cures extensively drug-resistant infections of pulmonary tuberculosis. In Vivo (2014) 0.76

The mechanism by which the phenothiazine thioridazine contributes to cure problematic drug-resistant forms of pulmonary tuberculosis: recent patents for "new use". Recent Pat Antiinfect Drug Discov (2013) 0.76

Physiological characterisation of the efflux pump system of antibiotic-susceptible and multidrug-resistant Enterobacter aerogenes. Int J Antimicrob Agents (2010) 0.76

Neuroleptic drugs in the treatment of tuberculosis: Minimal inhibitory concentrations of different phenothiazines against Mycobacterium tuberculosis. Tuberculosis (Edinb) (2016) 0.76

In vitro evaluation of novel inhalable dry powders consisting of thioridazine and rifapentine for rapid tuberculosis treatment. Eur J Pharm Biopharm (2016) 0.76

Thioridazine Alters the Cell-Envelope Permeability of Mycobacterium tuberculosis. J Proteome Res (2016) 0.76

Tentative susceptibility testing breakpoint for the neuroleptic drug thioridazine, a treatment option for multi- and extensively drug resistant tuberculosis. Int J Mycobacteriol (2012) 0.75

[Use of largactil in pulmonary tuberculosis]. Rev Esp Tuberc (1958) 0.75

Antimycobacterial activity of five efflux pump inhibitors against Mycobacterium tuberculosis clinical isolates. J Antibiot (Tokyo) (2015) 0.75